SNDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Syndax Pharmaceuticals's PE Ratio without NRI is 0.00. Syndax Pharmaceuticals's 5-Year EBITDA growth rate is 0.00%. Therefore, Syndax Pharmaceuticals's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Syndax Pharmaceuticals's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Syndax Pharmaceuticals's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Syndax Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Syndax Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Syndax Pharmaceuticals's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 0.00 | ||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Syndax Pharmaceuticals (NAS:SNDX) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Syndax Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael A Metzger | officer: President and COO | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
Neil Gallagher | officer: President, Head of R&D | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Keith A. Goldan | officer: Chief Financial Officer | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
Briggs Morrison | director, officer: Chief Executive Officer | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
William Meury | director | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Peter Ordentlich | officer: Chief Technology Officer | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451 |
Pierre Legault | director | P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312 |
Steve M Sabus | officer: Chief Commercial Officer | 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Keith Katkin | director | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Dennis Podlesak | director | C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Catherine Madigan | officer: Chief Medical Officer | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Alexander Nolte | officer: Chief Accounting Officer | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Fabrice Egros | director | C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451 |
Huber Martin H. Jr. | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Daphne Karydas | officer: Chief Financial Officer | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
From GuruFocus
By Marketwired • 03-03-2025
By PRNewswire • 01-03-2025
By Marketwired • 02-24-2025
By GuruFocus News • 02-25-2025
By PRNewswire • 01-30-2025
By GuruFocus News • 03-05-2025
By Marketwired • 02-10-2025
By PRNewswire • 01-08-2025
By GuruFocus News • 02-05-2025
By GuruFocus News • 02-15-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.